Patents by Inventor Christel Iffland
Christel Iffland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11884724Abstract: The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.Type: GrantFiled: August 4, 2020Date of Patent: January 30, 2024Assignee: Merck Patent GmbHInventors: Horacio G. Nastri, Christel Iffland, Olivier Leger, Qi An, Mark Cartwright, Sean D. McKenna
-
Publication number: 20230265187Abstract: The present disclosure provides antibodies that specifically bind to TIGIT. The antibodies find use in a variety of treatment, diagnostic, and monitoring applications, which are also described. For example, the antibody may be used to treat a patient for cancer, particularly a patient is also being treated or has been treated with an immune checkpoint inhibitor, e.g., a PD-1/PD-L1 inhibitor.Type: ApplicationFiled: June 29, 2021Publication date: August 24, 2023Inventors: Ellen COLLARINI, Shelley IZQUIERDO, Christel IFFLAND, William Don HARRIMAN
-
Patent number: 11597771Abstract: The present invention relates to antibodies with specificity for FGFR1. More particularly, the invention relates to monoclonal antibodies that bind specifically to and neutralize human, macaque and mouse forms of FGFR1 with high affinity. The invention also relates to nucleic acids encoding said antibodies, vectors for expression of these nucleic acids, and host cells for producing said antibodies. Further, the invention relates to the use of said antibodies in the diagnosis and/or treatment of cancers.Type: GrantFiled: November 21, 2017Date of Patent: March 7, 2023Inventors: Christel Iffland, Christina Esdar, Xinyan Zhao, Qi An, Johannes Yeh, Gang Hao, Lars Toleikis, Vanita Sood, David Nannemann, Robin Lytle, Bjoern Hock
-
Publication number: 20220403022Abstract: The present application relates to anti-TIGIT antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of infectious diseases and cancer.Type: ApplicationFiled: November 5, 2020Publication date: December 22, 2022Inventors: Dong ZHANG, Christie KELTON, Liwei LI, David NANNEMANN, Qi AN, Christel IFFLAND, Xinyan ZHAO, Johannes YEH
-
Publication number: 20220306762Abstract: The present disclosure provides antibodies that specifically bind to CD38. The antibodies find use in a variety of treatment, diagnostic, and monitoring applications, which are also described. The present disclosure provides antibodies that specifically bind to, and in some embodiments, inhibit CD38. A subject antibody specifically binds CD38 from humans and other mammals, e.g., monkey and mouse.Type: ApplicationFiled: June 26, 2020Publication date: September 29, 2022Inventors: Shelley Izquierdo, Ellen Collarini, Christel Iffland, William Don Harriman
-
Publication number: 20220298246Abstract: The present disclosure provides antibodies that specifically bind to B7-H3. The antibodies find use in a variety of treatment, diagnostic, and monitoring applications, which are also described. The present disclosure provides antibodies that specifically bind to B7-H3. A subject antibody specifically binds B7-H3 from humans and other mammals, e.g., monkey and mouse.Type: ApplicationFiled: June 26, 2020Publication date: September 22, 2022Inventors: Ellen Collarini, Shelley Izquierdo, Christel Iffland, William Don Harriman
-
Publication number: 20220081480Abstract: The invention is based, in part, upon the discovery of a family of antibodies that specifically bind human T Cell Immunoglobulin and Mucin Domain-3 (TIM-3). The antibodies contain TIM-3 binding sites based on the CDRs of the antibodies. The antibodies can be used as therapeutic agents as a monotherapy or in combination with another therapeutic agent. When used as therapeutic agents, the antibodies can be optimized, e.g., affinity-matured, to improve biochemical and/or biophysical properties and/or to reduce or eliminate immunogenicity, when administered to a human patient. The antibodies inhibit TIM-3 from binding to TIM-3 ligands, e.g., galectin-9, phosphatidylserine (PtdSer) and carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). The disclosed antibodies can be used to inhibit the proliferation of tumor cells in vitro or in vivo. When administered to a human cancer patient or an animal model, the antibodies inhibit or reduce tumor growth in the human patient or animal model.Type: ApplicationFiled: April 30, 2021Publication date: March 17, 2022Inventors: Dong Zhang, Xinyan Zhao, Qi An, David Nannemann, Rinat Zaynagetdinov, Vanita Sood, Christel Iffland
-
Publication number: 20220073616Abstract: The invention is based, in part, upon the discovery of a family of antibodies that specifically bind human T Cell Immunoglobulin and Mucin Domain-3 (TIM-3). More specifically, this invention relates to a method of treating cancer by administering an anti-TIM-3 antibody in combination with an anti-PD-L1/TGF? Trap fusion protein. When administered to a human cancer patient or an animal model, the antibodies inhibit or reduce tumor growth in the human patient or animal model.Type: ApplicationFiled: April 30, 2021Publication date: March 10, 2022Inventors: Mary Ruisi, Rinat Zaynagetdinov, Dong Zhang, Xinyan Zhao, Qi An, David Nannemann, Vanita Sood, Christel Iffland
-
Publication number: 20210054073Abstract: The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.Type: ApplicationFiled: August 4, 2020Publication date: February 25, 2021Inventors: Horacio G. Nastri, Christel Iffland, Olivier Leger, Qi An, Mark Cartwright, Sean D. McKenna
-
Patent number: 10759856Abstract: The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.Type: GrantFiled: March 9, 2017Date of Patent: September 1, 2020Assignee: Merck Patent GmbHInventors: Horacio G. Nastri, Christel Iffland, Olivier Leger, Qi An, Mark Cartwright, Sean D. McKenna, Vanita D. Sood, Gang Hao
-
Publication number: 20190367620Abstract: The present invention relates to antibodies with specificity for FGFR1. More particularly, the invention relates to monoclonal antibodies that bind specifically to and neutralize human, macaque and mouse forms of FGFR1 with high affinity. The invention also relates to nucleic acids encoding said antibodies, vectors for expression of these nucleic acids, and host cells for producing said antibodies. Further, the invention relates to the use of said antibodies in the diagnosis and/or treatment of cancers.Type: ApplicationFiled: November 21, 2017Publication date: December 5, 2019Inventors: CHRISTEL IFFLAND, CHRISTINA ESDAR, XINYAN ZHAO, QI AN, JOHANNES YEH, GANG HAO, LARS TOLEIKIS, VANITA SOOD, DAVID NANNEMANN, ROBIN LYTLE, BJOERN HOCK
-
Patent number: 10487147Abstract: The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.Type: GrantFiled: March 9, 2017Date of Patent: November 26, 2019Assignee: Merck Patent GmbHInventors: Horacio G. Nastri, Christel Iffland, Olivier Leger, Qi An, Mark Cartwright, Sean D. McKenna
-
Publication number: 20170253654Abstract: The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.Type: ApplicationFiled: March 9, 2017Publication date: September 7, 2017Inventors: Horacio G. Nastri, Christel Iffland, Olivier Leger, Qi An, Mark Cartwright, Sean D. McKenna
-
Publication number: 20170253653Abstract: The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.Type: ApplicationFiled: March 9, 2017Publication date: September 7, 2017Inventors: Horacio G. Nastri, Christel Iffland, Olivier Leger, Qi An, Mark Cartwright, Sean D. McKenna, Vanita D. Sood, Gang Hao
-
Patent number: 9624298Abstract: The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.Type: GrantFiled: November 21, 2012Date of Patent: April 18, 2017Assignee: Merck Patent GmbHInventors: Horacio G. Nastri, Christel Iffland, Olivier Leger, Qi An, Mark Cartwright, Sean D. McKenna
-
Patent number: 9534054Abstract: The invention relates to monoclonal antibodies against human CXCR5 and to their use in the treatment of autoimmune or inflammatory diseases, as well as cancers.Type: GrantFiled: April 30, 2014Date of Patent: January 3, 2017Assignee: ARES TRADING S.A.Inventors: Christine Power, Olivier Leger, Paul Bradfield, Horacio G. Nastri, Christel Iffland, Qi An
-
Publication number: 20140341917Abstract: The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.Type: ApplicationFiled: November 21, 2012Publication date: November 20, 2014Applicant: MERCK PATENT GMBHInventors: Horacio G. Nastri, Christel Iffland, Olivier Leger, Qi An, Mark Cartwright, Sean D. McKenna, Vanita D. Sood, Gang Hao